Cysteinyl
leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction.
The CysLT1receptor antagonist montelukast blocks bronchoconstriction induced by inhaled
leukotriene E4 in subjects with asthma.
The cysteinyl
leukotriene D4 receptors antagonist montelukast for the treatment of interstitial cystitis.
The researchers landed on their breakthrough after discovering that inflammatory molecules known as
leukotrienes are deregulated in Alzheimer's disease and related dementias.
Some asthma agents, such as montelukast, act as either leukotriene-related enzyme inhibitors (arachidonate 5-lipoxygenase) or
leukotriene receptor antagonists.
Recently, Hoxha and colleagues try to delineate the potential role of montelukast, the most described
leukotriene receptor antagonist, in the treatment of cardiovascular diseases.
The meta-analysis uncovered a significant association between omega-3 supplementation in reduction in thromboxane B2 in the blood of participants at high risk of cardiovascular disease and in
leukotriene B4 in the neutrophils of unhealthy subjects.
[16-20] Since inhaled or oral corticosteroids have not been shown to attenuate
leukotriene production in vivo [21], therefore, a
leukotriene receptor antagonist in combination with inhaled corticosteroid may confer additional benefits and could be the best combination.
Animal studies suggest that the marked increase in
leukotriene levels occurring during aspirin desensitization may play a role.
[3] Long-term studies support this approach in which
leukotriene receptor antagonist and theophylline are also the potential contenders.
We have previously found that montelukast, primarily a cysteinyl
leukotriene (CysLTj) receptor antagonist, exhibited secondary, neutrophil-directed anti-inflammatory properties, which appeared to be cAMP-mediated [26].